ACIONT, INC.

Medtech · Still private

A non-invasive topical drug delivery system (DSP Visulex) that applies dexamethasone sodium phosphate to treat uveitis and other ocular inflammatory conditions

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Medtech
Total capital: $5K

Federal grants: $5K; 1 award · 2015; Rank in peer group#74 of 1112
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 16 pending

Capital timeline

Latest events

May 2015Federal grantHealth and Human S · Phase II · Non-Invasive Treatment for Uveitis$5K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1112 peers

Line = median

Medtech · Device

Federal grants#74 · top 7%
Linked publications#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 16

Jan 6, 2022PendingOphthalmic CompositionsUSPTOApplication 17359120
Dec 10, 2020PendingLipoic Acid FormulationsUSPTOApplication 16869541
Mar 19, 2020PendingIntrascleral Drug Delivery Device And Associated MethodsUSPTOApplication 16559414

Show all 16 patent records

Ophthalmic CompositionsJan 6, 2022 · Application 17359120Pending
Lipoic Acid FormulationsDec 10, 2020 · Application 16869541Pending
Intrascleral Drug Delivery Device And Associated MethodsMar 19, 2020 · Application 16559414Pending
Non-invasive Ocular Drug Delivery DevicesJan 30, 2020 · Application 16512231Pending
Ophthalmic CompositionsJul 18, 2019 · Application 16155641Pending
Methods Of Treating A Subject With An Ocular Condition Responsive To Steroid TherapyApr 11, 2019 · Application 15727452Pending
Non-invasive Ocular Drug Delivery DevicesApr 11, 2019 · Application 15727529Pending
Cular Administration Of Immunosuppressive AgentsApplication PCTUS2006037909Pending
Methods And Devices For Sustained In-vivo Release Of An Active AgentApplication PCTUS2005039672Pending
Methods And Systems For Controlling And/or Increasing Iontophoretic FluxApplication PCTUS2004004126Pending
Lipoic Acid FormulationsApplication PCTUS2020031957Pending
Lipoic Acid FormulationsApplication 62844457Pending
Non-invasive Ocular Drug Delivery DevicesApplication PCTUS2018055080Pending
Ophthalmic CompositionsApplication 62569430Pending
Method And Device For Minimally Invasive Site Specific Ocular Drug DeliveryApplication PCTUS2007016850Pending
Intraocular Iontophoretic Device And Associated MethodsApplication PCTUS2006041541Pending

Recent research by its founders

Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules202029 cites
A Novel Ocular Drug Delivery System of Dexamethasone Sodium Phosphate for Noninfectious Uveitis Treatment20196 cites
Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial201816 cites

Glympse Bio, Inc.Similar federal contract value in Medtech · null in contracts
Laser Tissue Welding, IncSimilar federal contract value in Medtech · null in contracts
AXOSIM, INC.Similar federal contract value in Medtech · null in contracts
RESONANTIA DIAGNOSTICS, INC.Similar federal contract value in Medtech · null in contracts
OrthoCor Medical, Inc.Similar federal contract value in Medtech · null in contracts
HELIX ACOUSTICS, LLCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.